CERS News Alert Cerus Corp (CERS) 6.49 12/25/2014 14:05:07

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerus Corp (CERS) 6.49 $CERS

Interesting CERS Put And Call Options For August 2015
at The Street - Wed Dec 24, 11:43AM CST
Investors in Cerus Corp. saw new options become available this week, for the August 2015 expiration.
CERS: 6.49 (+0.29)

Today's Dead Cat Bounce Stock Is Cerus (CERS)
at The Street - Wed Dec 24, 9:02AM CST
Trade-Ideas LLC identified Cerus (CERS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CERS: 6.49 (+0.29)

Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Business Wire - Mon Dec 22, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation at an upcoming scientific congress.
CERS: 6.49 (+0.29)

Cerus Soaring On FDA Approval Of Intercept
Value Insight - at Seeking Alpha - Fri Dec 19, 7:47PM CST

CERS: 6.49 (+0.29), BAX: 74.45 (-0.04)

FDA clears expanded label for Cerus Intercept Blood System
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:13AM CST

CERS: 6.49 (+0.29)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST

KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)

FDA Approves INTERCEPT Blood System for Platelets
Business Wire - Thu Dec 18, 6:20PM CST
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet system is approved for ex vivo preparation of pathogen-reduced apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).
CERS: 6.49 (+0.29)

Nasdaq stocks posting largest percentage increases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CERS: 6.49 (+0.29), PTRY: 36.78 (+0.28), DRIV: 24.49 (+0.09), MTLS: 9.12 (-0.08), VOLC: 17.95 (+0.02), NPSP: 35.06 (+1.18), NYNY: 7.89 (+0.32), XNCR: 16.83 (+0.77), AREX: 6.98 (-0.11)

Cerus Up 44.4% Since SmarTrend Uptrend Call (CERS)
Comtex SmarTrend(R) - Thu Dec 18, 9:15AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 2 months, Cerus has returned 44.38% as of today's recent price of $6.10.
CERS: 6.49 (+0.29)

Strength Seen in Cerus (CERS): Stock Soars 22.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:25AM CST
Cerus (CERS) was a big mover last session, with shares rising roughly 23% on the day.
CERS: 6.49 (+0.29), ICUI: 83.38 (+1.63)

MGM Resorts and FedEx are big market movers
AP - Wed Dec 17, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
CERS: 6.49 (+0.29), DRIV: 24.49 (+0.09), FDX: 176.42 (-0.52), RT: 6.30 (+0.10), VOLC: 17.95 (+0.02), ASPX: 49.93 (-0.10), MSFT: 48.14 (-0.31), MGM: 20.77 (-0.17), XL: 34.26 (-0.11)

Stocks in the News: Analyst Coverage on Encana, Unisys, Salix, Cerus and Eli Lilly
PR Newswire - Wed Dec 17, 8:20AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Encana (NYSE: ECA), Unisys (NYSE: UIS), Salix (NASDAQ: SLXP), Cerus (NASDAQ: CERS), and Eli Lilly (NYSE: LLY). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CERS: 6.49 (+0.29), ECA: 13.73 (-0.03), SLXP: 114.92 (-1.18), UIS: 29.77 (-0.43), LLY: 70.16 (+0.42)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST

CERS: 6.49 (+0.29), FRO: 2.43 (-0.01), KNDI: 12.90 (+0.99), GFI: 4.37 (+0.13), CLF: 6.06 (-0.09), NVGN: 2.40 (-0.09), ASPX: 49.93 (-0.10), DRIV: 24.49 (+0.09), SID: 2.24 (-0.08), HALO: 9.34 (+0.31), VOLC: 17.95 (+0.02), POZN: 7.86 (+0.07), ICLD: 3.00 (-0.02), TASR: 26.86 (+0.84), DGLY: 15.62 (+0.82), SBGL: 7.13 (+0.20)

Cerus set for gap up at the open after Intercept approval
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:01AM CST

CERS: 6.49 (+0.29)

Cerus +20.3% AH; FDA approves Intercept for plasma
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 6:21PM CST

CERS: 6.49 (+0.29)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 4:42PM CST

NGL: 28.65 (-0.49), CERS: 6.49 (+0.29), MEG: 17.13 (-0.34), UWTI: 13.91 (-0.27), IAG: 2.41 (+0.06), CLF: 6.06 (-0.09), EWM: 13.45 (+0.06), EPAM: 48.84 (+0.33), CLNE: 5.25 (-0.15), ARO: 2.30 (-0.03)

FDA Approves INTERCEPT Blood System for Plasma
Business Wire - Tue Dec 16, 4:31PM CST
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma. The INTERCEPT plasma system is approved for ex vivo preparation of plasma in order to reduce the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion.
CERS: 6.49 (+0.29)

Hot Stock: Cerus, Shares Gain 6.7% (CERS)
Comtex SmarTrend(R) - Fri Dec 12, 11:36AM CST
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 6.7% to $4.91 on 1.1x average daily volume. Thus far today, Cerus has traded 1.1 million shares, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (6.7% to the Dow's -1.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.7%) during today's trading.
CERS: 6.49 (+0.29)

Health Care Equipment and Supplies Equities Scrutiny - Abbott Laboratories, Zimmer Holdings, Varian Medical Systems, Edwards Lifesciences, and Cerus
PR Newswire - Thu Dec 11, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), Varian Medical Systems Inc. (NYSE: VAR), Edwards Lifesciences Corporation (NYSE: EW), and Cerus Corporation (NASDAQ: CERS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 10, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,533.15, down 1.51% and the NASDAQ Composite closed at 4,684.03, down 1.73%. The S&P 500 finished the session 1.64% lower at 2,026.14. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 803.98, down 1.59%, whereas the index has advanced 8.03% in the previous three months. Register for your complimentary reports on these five stocks at:
CERS: 6.49 (+0.29), ZMH: 114.11 (+0.64), ABT: 45.70 (-0.02), VAR: 88.44 (+0.69), EW: 130.75 (+1.17)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading